Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Basic): 2021-2025

Historic EPS (Basic) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $0.25.

  • Kiniksa Pharmaceuticals International's EPS (Basic) rose 238.89% to $0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.49, marking a year-over-year increase of 476.92%. This contributed to the annual value of -$0.60 for FY2024, which is 400.00% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported EPS (Basic) of $0.25 as of Q3 2025, which was up 4.17% from $0.24 recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EPS (Basic) ranged from a high of $3.23 in Q3 2022 and a low of -$0.72 during Q1 2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's EPS (Basic) had a median value of -$0.06 in 2024 and averaged $0.02.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EPS (Basic) skyrocketed by 834.09% in 2022 and then crashed by 133.33% in 2024.
  • Kiniksa Pharmaceuticals International's EPS (Basic) (Quarterly) stood at -$0.52 in 2021, then skyrocketed by 111.54% to $0.06 in 2022, then spiked by 500.00% to $0.36 in 2023, then crashed by 133.33% to -$0.12 in 2024, then skyrocketed by 238.89% to $0.25 in 2025.
  • Its EPS (Basic) was $0.25 in Q3 2025, compared to $0.24 in Q2 2025 and $0.12 in Q1 2025.